On the upside
The Federal Communications Commission granted TerreStar (Nasdaq: TSTR) authority to integrate it satellite and terrestrial communications network to enhance its mobile wireless services.
Sunesis Pharmaceuticals (Nasdaq: SNSS) announced upbeat results from new nonclinical studies of its leukemia treatment voreloxin.
Barclays will pay approximately $25 million in cash to acquire the 700 New York Stock Exchange market maker assignments held by LaBranche (NYSE: LAB).
On the downside
MDRNA (Nasdaq: MRNA) will sell nearly 5.4 million common shares to raise approximately $5.5 million through a registered direct offering.
Cell Therapeutics (Nasdaq: CTIC) will sell $30 million worth of preferred stock and warrants to purchase common shares to two institutional investors through a registered offering.
America Movil (NYSE: AMX) offered $21 billlion to acquire rivals Telmex and Telmex Internacional in an effort to combine all three telecommunications companies.
In the broad market, declining issues barely edged out advancers by a slim margin on the NYSE while advancers outpaced decliners by more than 10 to 9 on Nasdaq. The Russell 2000 which tracks small cap stocks added a fraction to 644.